Promising therapeutic potential of tumor suppressor microRNAs for malignant pleural mesothelioma

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive and recalcitrant surface neoplasm that defies current multimodality treatments. MicroRNAs (miRNAs) are small noncoding RNAs that epigenetically regulate multiple gene networks and cellular processes. In cancer, miRNA dysregulation is associated with tumorigenesis, with tumor suppressor miRNAs underexpressed or lost, while oncogenic miRNAs are overexpressed. Consequently, miRNAs have emerged as potential therapeutic candidates. Because loss of tumor suppressors predominates the pathophysiology of MPM, re-expressing tumor suppressor miRNAs could be an effective therapeutic strategy. This review highlights the most promising MPM-specific tumor suppressor miRNAs that could be developed into novel therapeutics, the supporting data, and what is known about their molecular mechanism(s).

Keywords

Malignant pleural mesothelioma / microRNA / tumor suppressor / therapeutic

References

[1] Rupaimoole R.MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.Nat Rev Drug Discov2017;16:203-22

[2] Shah MY,Sood AK,Calin GA.MicroRNA therapeutics in cancer - an emerging concept.EBioMedicine2016;12:34-42 PMCID:PMC5078622

[3] Network NCCN. Malignant pleural mesothelioma (Version1.2022). Available from: https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManager?fileManagerId=13247 [Last accessed on 2 Dec 2022]

[4] Travis WD,Burke AP,Nicholson AG.Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart.J Thorac Oncol2015;10:1240-2

[5] Galateau-Salle F,Roggli V.The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification.J Thorac Oncol2016;11:142-54

[6] Tsao AS,Rimner A.New era for malignant pleural mesothelioma: updates on therapeutic options.J Clin Oncol2022;40:681-92 PMCID:PMC8853621

[7] Baas P,Nowak AK.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021;397:375-86

[8] Lo Russo G,Capece M.MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a literature review.Front Oncol2018;8:650 PMCID:PMC6308141

[9] Fassina A,Guzzardo V.Epithelial-mesenchymal transition in malignant mesothelioma.Mod Pathol2012;25:86-99

[10] Pass HI,Ivanov S.hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.Cancer Res2010;70:1916-24 PMCID:PMC2831149

[11] Birnie KA,Ng DC.Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma.Mol Cancer Res2015;13:1106-18

[12] Zhang Q,Cai H.CircPLK1 acts as a carcinogenic driver to promote the development of malignant pleural mesothelioma by governing the miR-1294/HMGA1 pathway.Biochem Genet2022;60:1527-46

[13] Xu Y,Merritt RE.miR-1 induces growth arrest and apoptosis in malignant mesothelioma.Chest2013;144:1632-43 PMCID:PMC4694093

[14] Amatya VJ,Kushitani K,Takeshima Y.Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma.Int J Oncol2016;48:1599-607

[15] Bueno R,Goldstein LD.Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.Nat Genet2016;48:407-16

[16] Guo G,Goparaju C.Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.Cancer Res2015;75:264-9

[17] Illei PB,Zakowski MF.Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.Clin Cancer Res2003;9:2108-13

[18] Vassilev LT,Graves B.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science2004;303:844-8

[19] Liu J,Zhao Y.MicroRNA Control of p53.J Cell Biochem2017;118:7-14

[20] Andersen M,Ravn J,Andersen CB.Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.J Mol Diagn2014;16:418-30

[21] Cioce M,Canu V.Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.Oncogene2014;33:5319-31 PMCID:PMC4687459

[22] Singh A,Srivastava A.MicroRNA-215-5p treatment suppresses mesothelioma progression via the MDM2-p53-signaling axis.Mol Ther2019;27:1665-80 PMCID:PMC6731470

[23] Williams M,Kirschner MB.Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.Oncotarget2019;10:4125-38 PMCID:PMC6609241

[24] Williams M,Phimmachanh M,van Zandwijk N.Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways.Cancer Drug Resist2019;2:1193-206 PMCID:PMC9019216

[25] Pinelli S,Corradi M.A comparison between the effects of over-expression of miRNA-16 and miRNA-34a on cell cycle progression of mesothelioma cell lines and on their cisplatin sensitivity.Cancer Treat Res Commun2021;26:100276

[26] Menges CW,Altomare D.Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.Cancer Res2014;74:1261-71 PMCID:PMC3945416

[27] Kubo T,Tsukuda K.Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma.Clin Cancer Res2011;17:4965-74

[28] Maki Y,Toyooka S,Kubo T,Ueno T,Muraoka T,Yamamoto H,Kishimoto T,Miyoshi S.MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells.Anticancer Res2012;32:4871-5.

[29] Ueno T,Fukazawa T.Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.Acta Med Okayama2014;68:23-6

[30] Gray SG.Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.BMC Pulm Med2021;21:148 PMCID:PMC8097826

[31] Cantini L,Gooijer CJ.Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program.Transl Lung Cancer Res2020;9:1169-79 PMCID:PMC7481613

[32] Okada M,Aoe K.Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese phase II study in malignant pleural mesothelioma (MERIT).Clin Cancer Res2019;25:5485-92

[33] Reid G,Kirschner MB.Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.Ann Oncol2013;24:3128-35

[34] Kao SC,Williams M.Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma.J Thorac Oncol2017;12:1421-33

[35] van Zandwijk N,Kao SC.Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.Lancet Oncol2017;18:1386-96

[36] Williams M,Cheng YY.miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.Oncotarget2015;6:23480-95 PMCID:PMC4695131

[37] Santarelli L,Staffolani S.Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.PLoS One2011;6:e18232 PMCID:PMC3069972

[38] Tomasetti M,Staffolani S.MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function.Antioxid Redox Signal2014;21:2109-25 PMCID:PMC4215384

[39] Tomasetti M,Manzella N.MicroRNA-126 induces autophagy by altering cell metabolism in malignant mesothelioma.Oncotarget2016;7:36338-52 PMCID:PMC5095004

[40] Singh A,Pahwa R,Schrump DS.MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis.Mol Ther Nucleic Acids2021;24:669-81 PMCID:PMC8093312

[41] Ivanov SV,Lopez P.Pro-tumorigenic effects of miR-31 loss in mesothelioma.J Biol Chem2010;285:22809-17 PMCID:PMC2906272

[42] Moody HL,Maher SG.MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma.Mol Ther Nucleic Acids2017;8:317-29 PMCID:PMC5537169

[43] Matsumoto S,Hamasaki M,Umemura T.Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.Med Oncol2014;31:303

[44] Khodayari N,Goldberg EP.EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.Cancer Gene Ther2011;18:806-16

[45] Truini A,Nadal E.Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.Oncotarget2017;8:68627-40 PMCID:PMC5620283

[46] Khodayari N,Lee H,Nasreen N.MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells.Am J Cancer Res2016;6:1996-2009. PMCID:PMC5043109

[47] Ramírez-Salazar EG,Vázquez-Manríquez ME.Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.Exp Mol Pathol2014;97:375-85

[48] Hmeljak J,Hoadley KA.Integrative molecular characterization of malignant pleural mesothelioma.Cancer Discov2018;8:1548-65 PMCID:PMC6310008

[49] Johnson TG,Cheng YY.Dysregulated expression of the MicroRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma.J Thorac Oncol2018;13:258-72

[50] Reid G,Pavlakis N.Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.Epigenomics2016;8:1079-85

[51] Majumder P,Wang Z.Surface-fill hydrogel attenuates the oncogenic signature of complex anatomical surface cancer in a single application.Nat Nanotechnol2021;16:1251-9 PMCID:PMC8595541

[52] Napoli F,Izzo S.Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition.Virchows Arch2022;481:233-44

[53] Tanaka N,Soh J.Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells.Oncol Rep2013;29:2169-74

[54] Muraoka T,Toyooka S.The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.Lung Cancer2013;82:485-90

[55] Munson PB,Farina NH,Shukla A.Exosomal miR-16-5p as a target for malignant mesothelioma.Sci Rep2019;9:11688 PMCID:PMC6690928

[56] Monaco F,Vodret S.Force-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126 induces tumour cell killing.Transl Oncol2022;20:101400 PMCID:PMC8956928